Oxidative DNA Damage Enhancement by Vitamin C Among Narghile Smokers and Non-smokers (DNA Damage)

August 24, 2025 updated by: Nora Tariq Mohammed
This study aims to evaluate oxidative DNA damage among hookah smokers compared to non-smokers by measuring biomarkers of oxidative stress in blood samples. The objective is to determine the impact of hookah smoking on DNA integrity and overall oxidative status in adults.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Hookah smoking has become increasingly popular in many regions, yet its potential impact on oxidative stress and DNA integrity is not fully understood. This study aims to investigate the level of oxidative DNA damage among hookah smokers compared to non-smokers by analyzing biomarkers in blood samples. A case-control observational design will be used, involving two groups of adult participants: regular hookah smokers and age-matched non-smokers. Blood samples will be collected from all participants and analyzed for markers of oxidative stress, including 8-hydroxy-2'-deoxyguanosine (8-OHdG) and malondialdehyde (MDA), using validated biochemical methods. The findings are expected to provide insights into the biological consequences of hookah smoking and support the development of public health interventions.

Study Type

Interventional

Enrollment (Actual)

96

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Iraq
    • semel
      • Dihok, semel, Iraq
        • University of Duhok

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults aged 18-30 years

Current narghile (hookah) smokers for at least 1 year

Willing to provide informed consent

Exclusion Criteria:

  • Healthy participant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Narghile nonsmokers vitamin C taking
this group of participant take vitamin C for one month, and they are healthy volunteers
Dietary supplement: Vitamin C (Ascorbic Acid) regularly has been taken
Experimental: Narghile smokers
this group take vitamin c supplent for one month period and are healthy.
Dietary supplement: Vitamin C (Ascorbic Acid) regularly has been taken

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxidative DNA damage
Time Frame: Baseline and after 1 month
Measurement of plasma MDA concentration using the thiobarbituric acid reactive substances (TBARS) method to assess oxidative stress in participants before and after 1-month Vitamin C supplementation and measuring oxidative stress marker and TAOC
Baseline and after 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nora Tariq Mohammed

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2024

Primary Completion (Actual)

December 10, 2024

Study Completion (Actual)

March 10, 2025

Study Registration Dates

First Submitted

July 16, 2025

First Submitted That Met QC Criteria

August 24, 2025

First Posted (Estimated)

August 26, 2025

Study Record Updates

Last Update Posted (Estimated)

August 26, 2025

Last Update Submitted That Met QC Criteria

August 24, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UoD-ODNS-2025-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vitamin C (Ascorbic Acid) regularly has been taken

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe